Natural Product (NP) Details
General Information of the NP (ID: NP0515) | |||||
---|---|---|---|---|---|
Name |
Iloprost
|
||||
Synonyms |
ILOPROST; Ciloprost; Ventavis; Iloprostum; 78919-13-8; ZK 36374; ZK-36374; CHEMBL494; CHEBI:63916; [3H]-Iloprost; Endoprost; Ilomedin; Ventavis (TN); ZK 00036374; (16R,S)-methyl-18,18,19,19-tetradehydro-6a-carbaprostaglandin I2; 73873-87-7; (5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]hexahydropentalen-2(1H)-ylidene]pentanoic acid; Iloprostum [Latin]; SR-05000001498; Iloprost [USAN:INN:BAN]; Ilomedine; BAY Q6256; Iloprost (USAN/INN); SCHEMBL6083382; Iloprost, >=98% (HPLC); BAY-q-6256; DTXSID2041046; BDBM23954; HMS2090A19; HY-A0096; SH-401; (16R,S)-Methyl-18,18,19,19-tetradehydro-6a-carbaprostaglandin I(sub 2); AKOS024456922; CS-5586; DB01088; (E)-5-(3aS,4R,5R,6aS)-5-Hydroxy-4((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-inyl)perhydropentalen-2-yliden)valeriansaeure; K395; Pentanoic acid, 5-(hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2(1H)-pentalenylidene)-; ZK-00036374; D02721; ACETICACID2-TERT-BUTYL-4-METHYLPHENYLESTER; J-502615; SR-05000001498-1; SR-05000001498-2; BRD-A45664787-001-01-4; BRD-A45664787-001-02-2; Q20817139; (1S,2R,3R,5S)-7-[(E)-4-carboxybutylidene]-2-[(3S,1E)-3-hydroxy-4-methyl-6-octyne-1-enyl]-3-hydroxybicyclo[3.3.0]octane; (5E)-5-[(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyl-1-octen-6-ynyl]-2(1H)-pentalenylidene]pentanoic acid; (E)-(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl)-delta(sup 2(1H),delta)-pentalenevaleric acid; (Z)-5-((3aS,4R,5R,6aS)-5-hydroxy-4-((3S,E)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl)hexahydropentalen-2(1H)-ylidene)pentanoic acid; 5-[(2E,3aS,4R,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]-octahydropentalen-2-ylidene]pentanoic acid
Click to Show/Hide
|
||||
Species Origin | Homo sapiens ... | Click to Show/Hide | |||
Homo sapiens | |||||
Disease | Pulmonary hypertension [ICD-11: BB01] | Approved | [1] | ||
Structure |
![]() |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C22H32O4
|
||||
PubChem CID | |||||
Canonical SMILES |
CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O
|
||||
InChI |
1S/C22H32O4/c1-3-4-7-15(2)20(23)11-10-18-19-13-16(8-5-6-9-22(25)26)12-17(19)14-21(18)24/h8,10-11,15,17-21,23-24H,5-7,9,12-14H2,1-2H3,(H,25,26)/b11-10+,16-8+/t15?,17-,18+,19-,20+,21+/m0/s1
|
||||
InChIKey |
HIFJCPQKFCZDDL-ACWOEMLNSA-N
|
||||
CAS Number |
CAS 78919-13-8
|
||||
ChEBI ID | |||||
TTD Drug ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Montelukast | Asthma | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Down-regulation | Expression | IL6 | Molecule Info |
Pathway MAP
|
|
Experimental
Result(s) |
Combined use of iloprost and montelukast may reduce ischemic damage in transient spinal cord ischemia and may provide better neurological outcome. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Prostaglandin E2 receptor EP2 (PTGER2) | Molecule Info | [3] | |
KEGG Pathway | cAMP signaling pathway | Click to Show/Hide | ||
2 | Neuroactive ligand-receptor interaction | |||
3 | Inflammatory mediator regulation of TRP channels | |||
4 | Renin secretion | |||
5 | Pathways in cancer | |||
Reactome | Prostanoid ligand receptors | Click to Show/Hide | ||
2 | G alpha (s) signalling events | |||
WikiPathways | Prostaglandin Synthesis and Regulation | Click to Show/Hide | ||
2 | GPCRs, Class A Rhodopsin-like | |||
3 | Ovarian Infertility Genes | |||
4 | Small Ligand GPCRs | |||
5 | GPCR ligand binding | |||
6 | GPCR downstream signaling |
